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Abstract
Background: A replication defective influenza A vaccine virus (delNS1 virus) was developed. Its attenuation is due to potent
stimulation of the innate immune system by the virus. Since the innateimmune system can also target cancer cells, we reasoned
that delNS1 virus induced immune-stimulation should also lead to the induction of innate cytotoxic effects towards cancer cells.
Methodology/Principal Findings: Peripheral blood mononuclear cells (PBMCs), isolated CD56+, CD3+, CD14+ and CD19+
subsets and different combinations of the above subsets were stimulated by delNS1, wild type (wt) virus or heat inactivated
virus and co-cultured with tumor cell lines in the presence or absence of antibodies against the interferon system.
Stimulation of PBMCs by the delNS1 virus effectively induced cytotoxicity against different cancer cell lines. Surprisingly,
virus induced cytotoxicity was exerted by all major subtypes of PBMCs including CD56+, CD3+, CD14+ and CD19+ cells.
Virus induced cytotoxicity in CD3+, CD14+ and CD19+ cells was dependent on virus replication, whereas virus induced
cytotoxicity in CD56+ cells was only dependent on the binding of the virus. Virus induced cytotoxicity of isolated cell
cultures of CD14+, CD19+ or CD56+ cells could be partially blocked by antibodies against type I and type II (IFN) interferon.
In contrast, virus induced cytotoxicity in the complete PBMC preparation could not be inhibited by blocking type I or type II
IFN, indicating a redundant system of activation in whole blood.
Conclusions/Significance: Our data suggest that apart from their well known specialized functions all main subsets of
peripheral blood cells also initially exert a cytotoxic effect upon virus stimulation. This closely links the innate immune system
to the adaptive immune response and renders delNS1 virus a potential therapeutic tool for viro-immunotherapy of cancer.
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Introduction
Influenza A virus effectively induces the adaptive and the innate
immune response. Stimulation of the adaptive immune response
has been regarded as substantial for viral clearance for a long time.
In contrast, the relevance of the stimulation of the innate immune
system for viral clearance became recently evident when Gazit et
al. demonstrated that mice lacking the natural killer (NK) cell
receptor Ncr-1 die from otherwise non-lethal influenza A virus
infection [1]. NK-cells which are stimulated by the viral
hemagglutinin are regarded as the main protagonists of virus
induced cytotoxicity of the innate immune system. However,
innate cytotoxicity does not seem to be restricted to NK-cells. A
plasmacytoid dendritic cell line is also able to exert a cytotoxic
effect after contact with influenza A virus [2]. Thus, different cell
types might contribute to virus induced innate cytotoxicity.
Apart from the relevance for viral infections, the innate immune
system also provides multiple ways of tumor cell destruction due to
its potency of effective cytotoxicity towards degenerated cells. It
was possible to treat murine cancer by adoptive transfer of
splenocytes, bone marrow cells or enriched peripheral macro-
phages from cancer resistant CR mice [3]. The tumor ablative
effect of leukocytes is not restricted to a single cell type but transfer
of multiple subsets of leukocytes [4] can promote cytotoxic effects.
Tumor ablation by induction of the innate immune system has
already led to clinical success. Stimulating toll like receptor (TLR)
7/8 with imiquimod leads to therapeutic effects on basaliomas.
This appears to be mediated by cytotoxic activity of dendritic cells
present in the tumor tissue [5]. Thus, efficient stimulation of cells
of the innate immune system might offer a therapeutic window for
cancer therapy in humans [6].
Therapeutic stimulation of the innate immune system may also
be induced by viruses. Specifically, oncolytic viruses-viruses which
have been generated to conditionally replicate in the tumor tissue
[7]-might exert such effects [8]. We have previously developed the
first prototype of an oncolytic influenza A virus, based on a
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restricts the virus to replication in protein kinase R (PKR)- and
IFN- defective tumor cells but not in normal cells [9,10]. In
general, influenza A viruses might be attractive immune stimulants
since they effectively activate the endosomal TLR 3 and 7 [11,12].
In addition to this property, NS1 deletion viruses have a specific
immune stimulatory phenotype, since the virus lacks its natural
viral antagonist of the IFN pathway. Consequently, the NS1
deletion virus effectively induces cytokines of the innate immune
system such as TNF, IL-1b and type I IFN [13–15]. The induction
of those cytokines is explained by the lack of inhibition of RIG-I
[16]. Due to this immune stimulatory property and its attenuated
nature [17] the NS1 deletion virus seems specifically attractive for
viro-immunotherapy of cancer patients.
For example, Efferson et al. [18] have shown, that a prostate
tumor cell line infected with influenza virus expressing a truncated
NS1 protein activates cytolytic CD8+ cells to recognize non-
infected tumor cells. Activation of those antigen-specific CD8+
cytotoxic T-lymphocytes by virus infected tumor cells was
achieved by 6 days of co-culture. This stimulation of the adaptive
arm of the immune system was due to the inherent property of the
virus to induce cross-presentation.
Here we tested whether direct stimulation of PBMCs by the
virus is also able to induce an immediate innate cytotoxic response
to cancer cells. Surprisingly, we found that virus induced innate
cytotoxicity is not restricted to NK-cells or monocytes. Immediate
cytotoxic activity was also observed in CD3+ T-lymphocytes and
in CD19+ B-lymphocytes. The latter effect appears to largely
depend on viral replication and was partially attenuated by
antibodies against type I and type II interferons. Our results
indicate that viral infection stimulates all major subsets of PBMCs
to exert an immediate cytotoxic function.
Results
PBMCs stimulated by influenza A NS1 deletion virus exert
cytotoxic effects on cancer cell lines
First we investigated whether PBMCs of healthy donors can be
stimulated by ex vivo infection with wild-type virus versus
replication defective influenza A delNS1 virus to induce anti-
tumor cytotoxicity. Since multiple publications have shown that
cell-cell interactions between immunologically active cells are
important for efficient immune-stimulation, it seemed vital to let
these cell-cell interactions occur in a total PBMC population.
PBMCs were infected/stimulated with wt PR8 influenza virus,
heat-inactivated wt PR8 influenza virus or delNS1 virus at a low
multiplicity of infection (m.o.i.) of 0.02. As shown in fig. 1 virus-
stimulated PBMCs generally displayed a strong cytotoxic effect
against the melanoma cell line A375 as compared with non-
infected PBMCs. This effect was reproducible for PBMCs isolated
from different donors. Importantly, there was no difference in the
stimulatory capacity between wt influenza virus and replication
defective delNS1 virus, whereas the heat-inactivated wt virus was
10–20% less effective. We then tested whether delNS1 stimulated
PBMCs are also able to kill other tumor cell lines such as MCF-7,
a human breast cancer cell line, CaCo-2, a human colon cancer
line, SK-Mel28, another human melanoma line and GSJO, a
human medullary thyroid carcinoma cell line. All targets were
efficiently killed by virus activated PBMCs (fig. 2).
Since cancer is an immune-compromised status, we wondered
whether infection of PBMCs from cancer patients would also
stimulate the immune response against tumor cells. For this
purpose we isolated PBMCs from 2 patients suffering from
medullary thyroid carcinoma, stimulated these cells with delNS1
as described above and co-cultured them with the primary
medullary thyroid carcinoma cell line GSJO. Infection of PBMCs
with delNS1 in both patients increased cytotoxic effects against
tumor cells, in comparison to non-infected control PBMCs (fig. 3).
All of the above described experiments with human PBMCs
were performed in the allogeneic system. In this setting virus-
enhanced cytotoxic activity of PBMCs against tumor cells could be
primarily based on the HLA-mismatch. To evaluate this possibility
we performed cytotoxicity experiments in a mouse autologous
tumor system. Purified splenocytes from BALB/c mice were
infected with delNS1 (m.o.i.=0.02) which led to a significant
induction of cytotoxicity of spleen cells against syngeneic C-26
colon carcinoma cells as compared to non-activated splenocytes
(fig. 4).
Figure 1. Induction of an anti-tumor cytotoxic immune response by PBMCs infected with influenza A variants. PBMCs were mock-
treated or infected with delNS1 virus, wt PR8 and heat-inactivated wt PR8 (m.o.i.=0.02) and were incubated for 24 hours. Then PBMCs were co-
cultured with the target A375 cells for 24 hours and cytotoxicity was assessed thereafter. One representative result out of three independent
experiments, each performed with PBMCs derived from a different donor, is shown.
doi:10.1371/journal.pone.0004122.g001
Virus Induced Cytotoxicity
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delNS1 virus mediated anti-tumor cytotoxicity
To analyze whether delNS1 induced cytotoxicity requires
cellular contact between target cells and PBMCs, virus-activated
PBMCs and A375 melanoma cells were separated by a semi-
permeable membrane in a transwell system and co-cultured in the
effector to a target ratio of 25:1. The virus-induced cytotoxic effect
was reduced to 50% when the cells were separated (fig. 5),
demonstrating that the cytotoxic effect of PBMCs depended on
both cellular contact and soluble factors. In order to investigate
whether those soluble cytotoxic factors are produced upon viral
infection and/or whether they require communication (feedback)
between tumor-derived soluble factors and PBMCs during the
24 hours of co-culture, we performed an additional experiment.
We treated tumor cells solely with the supernatant derived from
PBMCs 24 h post infection with delNS1 virus. No difference
Figure 2. Effect of mock-treated or delNS1 infected PBMCs on tumor cells of different tissue origin. PBMCs were infected with delNS1
virus (m.o.i.=0.02) and kept for 24 hours. Then the PBMCs were co-cultured with the target cells MCF-7, CaCo-2, Sk-Mel 28 or GSJO for 24 hours and
cytotoxicity was assessed thereafter. One representative result in percentage of cytotoxicity is shown out of two independent experiments, each
performed with PBMCs derived from a different donor.
doi:10.1371/journal.pone.0004122.g002
Figure 3. Induction of an anti-tumor cytotoxic immune response by PBMCs derived from patients suffering from medullary thyroid
carcinoma. PBMCs were infected with delNS1 virus (m.o.i.=0.02) or mock-treated and incubated for 24 hours. Then the PBMCs were co-cultured
with the target A375 cells for 24 hours and cytotoxicity was assessed. Results in percentage of cytotoxicity are shown for two independent
experiments.
doi:10.1371/journal.pone.0004122.g003
Virus Induced Cytotoxicity
PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4122between the transwell system and the supernatant-based experi-
ment was observed, arguing against the feedback circle (fig. 5).
Since cytotoxicity is partially mediated by PBMC- supernatant
we further investigated whether viral progeny could be involved in
the cytotoxic effect. We first determined whether infectious viral
particles are present in the supernatant of PBMCs infected with
delNS1 virus. We found that 5610
6 delNS1 infected PBMCs
release on average 25 infectious particles into the supernatant.
This would correspond to 0.6 infectious particles present in the co-
culture experiments done at the 25:1-effector:target ratio,
corresponding to an m.o.i.,0.0001. Although this amount of
infectious virus particles was very low, we further determined
whether delNS1 virus is able to lyse tumor cells in our setting. We
used a more than 100-fold higher concentration of the virus and
incubated A375, SK-Mel 28, CaCo-2 and MCF-7 tumor cells with
delNS1 at the m.o.i. of 0.02 and 0.2. We did not observe any
cytotoxicity in the cancer cell lines (fig. S1). To further rule out a
possible contribution of progeny virus we performed a co-culture
experiment of PBMCs and cancer cells in the presence of a
neutralizing anti-influenza antibody. The delNS1-virus stimulated
PBMCs induced the same level of cytotoxicity towards tumor cells
irrespective of the presence of neutralizing antibody (fig. S2).
Characterization of immunological markers in delNS1
virus infected PBMCs
We next determined whether delNS1 virus led to an increase of
specific subsets of PBMCs. PBMCs were stimulated with the virus
and analyzed 24 hours post infection by flow cytometry. As shown
in fig. 6a the number of lymphocytes did not change dramatically
after infection with delNS1 influenza virus. A significant alteration
in response to viral infection was only observed for the CD14+
population, which was more diminished in the virus treated group
as compared to the untreated group. No cell population was
considerably augmented by the virus. Although the overall
number of lymphocyte counts did not change substantially, the
expression of CD69 did. This activation marker demonstrated a
considerable increase to 52% after viral infection as compared to
12% in non-infected cells. The expression of the NK receptor
NKG2D was not significantly increased in response to the virus.
Furthermore, we determined the intracellular expression of the
apoptosis inducing molecules granzyme B and perforin (fig. 6b).
Although delNS1 virus triggered an up-regulation of these
molecules in PBMCs derived from some individuals there was
no significant rise of mean levels. The individual up-regulation did
not correlate with the intensity of the cytotoxic effect of the
respective PBMCs against tumor cells.
The delNS1 virus has been shown to substantially induce pro-
inflammatory cytokines such as IL-1b, TNF, IFNa, IL-6, and
IFNc in primary monocytes [14,19] and/or dendritic cells [15].
Figure 4. Induction of an anti-tumor cytotoxic immune response by virus infected splenocytes from BALB/c mice against a
syngeneic tumor. Splenocytes were mock-treated or infected with delNS1 virus (m.o.i.=0.02) and incubated for 24 hours. Then splenocytes were
co-cultured with the target C-26 cells for 24 hours and cytotoxicity was assessed thereafter. One representative result in percentage of cytotoxicity is
shown from three independent experiments.
doi:10.1371/journal.pone.0004122.g004
Figure 5. Effect of mock-treated or infected PBMCs on tumor
cells under different co-culture conditions. PBMCs were infected
with delNS1 virus (m.o.i.=0.02) or mock-treated and incubated for
24 hours. Then the PBMCs were either co-cultured directly with the
target A375 cells (co-culture) or were kept without cellular contact to
target cells (transwell). Alternatively, target cells were only supplied
with the 24 hour supernatant of PBMC cultures (supernatant). The
effector to target ratio was 25:1. After 24 hours cytotoxicity was
assessed. Mean results (6SD) in percentage of cytotoxicity are shown
from three independent experiments, each performed with PBMCs
derived from a different donor.
doi:10.1371/journal.pone.0004122.g005
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cultures. The delNS1 virus induced high levels of IFNa, IL-6, IL-
8, IFNc, TNFa and IL-1b, low levels of IL-10 but no IL-12p70
and no IL-4 (data not shown).
The role of PBMC subsets in delNS1 virus induced
cytotoxicity
In previous reports CD56+ cells have been associated with a
strong cytotoxic activity in influenza A virus infection. Moreover,
cytotoxic effects of immune-mediators produced by CD14+ cells
have been described for other viruses. CD3+ cells are generally
known as cytotoxic subsets with regard to adaptive immunity.
Therefore we initially focused on these three subsets. In order to
evaluate which subsets of cells are important for the delNS1
induced anti-tumor cytotoxicity, we next conducted effector cell
depletion experiments. Depletion of CD3+, CD14+ or CD56+
cells was performed before infection with delNS1, using magnetic
beads labeled with the respective antibodies. To verify depletion,
the remaining cell population was analyzed by flow cytometry
which consistently revealed purification grades of .95%.
Depletion of a single subset had no effect on delNS1 induced
cytotoxicity of PBMCs against tumor cells (data not shown).
We then performed double depletion experiments of selected
cell types. Depletion of CD14+ and CD56+ (,1% CD14+ and
,2% CD56+) as well as depletion of CD14+ and CD3+ (,3%
CD14+ and ,15% CD3+) was still associated with killing activity
of more than 80% as compared to total PBMCs. Depletion of
CD3+ and CD56+ (,2% CD3+ and ,1% CD56+) reduced
killing to 50% (data not shown).
According to the data above it seemed likely that more than two
of the major cell fractions of PBMCs contribute to delNS1 virus
induced cytotoxicity to cancer cell lines. Therefore we determined
the cytotoxic effect for each subset separately. For this purpose
cells were positively selected by antibody-coupled magnetic beads
and afterwards stimulated with the virus. Surprisingly, after
24 hours of co-culture with the melanoma cell line A375, not
only CD56+ and CD3+ cells, but also CD19+ and CD14+ cells
induced cytotoxicity (fig. 7). Since CD3+ selected cells still
contained the CD3+CD56+ NKT-cells, we also included a
CD56+ depletion step after CD3+ selection resulting in .90%
CD3+ and ,3% CD56 positive cells as verified by flow cytometry.
The purified T-cell population (CD3+ CD56-) showed the same
level of cytotoxicity as the mixture of CD3+CD56- and
CD3+CD56+ cells (data not shown). Stimulation of single cell
fractions with heat-inactivated virus, which binds to the viral cell
receptor but cannot replicate, still induced cytotoxicity in CD56+
cells but not in CD14+, CD19+ or CD3+ cells, indicating that live
virus is essential for activation of the latter cell types. CD69
expression was induced by live virus in CD19+, CD56+ and CD3+
cells but not by heat-inactivated delNS1 virus (table 1). Thus,
CD69 expression corresponds to live virus infection but not
necessarily to virus induced cytotoxicity.
Analysis of mediators involved in delNS1 virus induced
cytotoxicity
Using stimulating virus at low m.o.i. virus stimulated cytotox-
icity also depends on a second wave of cytokine activation
expressed by non-infected cells. We therefore first determined
whether there was a specific uniform cytokine pattern associated
with virus induced cell activation of monocultures. We could not
detect IL-2, IL-4, IL-5, IL-10, IL-12(p70) and IL-13 above
background levels in any of the monocultures. IFNa was produced
by all cell fractions except the CD3+ lymphocytes. The latter did
not produce any of the here tested common cytokines related to
immune activation. It should be noted that plasmacytoid dendritic
cells, which are known to generate large quantities of IFNa in the
Figure 6. Expression of extracellular and intracellular markers in PBMCs after infection with delNS1 virus. (a) Surface marker expression
of mock-treated or infected PBMCs with delNS1 virus was evaluated. PBMCs were infected with delNS1 virus (m.o.i.=0.02) or not infected and
cultured for 24 hours. Then the indicated markers were assessed by flow cytometry using specific fluorescent antibodies. Mean results and standard
deviation for the percentage of positive cells are shown from three independent experiments, each performed with cells derived from a different
donor. (b) Intracellular marker expression of comparably treated PBMCs was measured after antibody staining of permeabilized cells. Mean results
(6SD) for the percentage of positive cells are shown from three independent experiments, each performed with cells derived from a different donor.
doi:10.1371/journal.pone.0004122.g006
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fractions, since cells were positively selected by antibodies to CD3,
CD14, CD56 or CD19. IFNc was only produced in high amounts
by CD56+ cells, suggesting a possible contribution of this cytokine
in activation of this subpopulation. TNF was produced by CD14+
cells and to a lesser extend by CD19+ and CD56+ cells. IL-6
showed a similar expression pattern as IFNa in monocultures
(table 2). In PBMCs all cytokines which were also found in
monocultures (TNF, IL-6, and type I and type II IFN) were
induced to high levels, indicating that cell-cell interaction and
dendritic cells present in PBMCs modified the cytokine pattern. A
comparison of the absolute amounts of cytokines found in PBMCs
with the amounts found in isolated monoculture is difficult, since
the number of cells of a defined cell type in PBMCs is less than the
number of cells in the monocultures. However, a comparison
indicates that high levels of cytokines present in PBMCs are not
critically essential for activation of cytotoxicity, since they are not
found in monocultures. Moreover, a comparison suggests possible
contributions of single subsets to the cytokine response in the
complete set of PBMCs.
In order to determine the contribution of cytokines which
mediate the induction of virus-induced killing in PBMCs-subsets
we blocked the cytokine production in monocultures. We focused
on the IFN system, since IFNs are associated with tumor cell
killing. For example, IFNa promotes NK- and CTL-mediated
anti-tumor responses [20]. Moreover, type I and type II IFN are
associated with adenovirus-mediated oncolysis [21]. The combi-
nation of type I and type II IFN blocking antibodies with an IFNa
receptor antibody was able to block cytotoxic activity of the
CD14+ monoculture by more than 50% (fig. 8). For CD19+ cells
the antibody combination was able to lower cytotoxicity by about
Figure 7. Induction of an anti-tumor cytotoxic immune response by infected monocultures. CD14+ (a), CD56+ (b), CD3+ (c) and CD19+
cells (d) were infected with delNS1 virus or heat-inactivated delNS1 (m.o.i.=0.02) and incubated for 24 hours. Then the cells were co-cultured with
the target A375 cells for 24 hours and cytotoxicity was assessed. One representative result in percentage of cytotoxicity is shown of three
independent experiments, each performed with cells derived from a different donor.
doi:10.1371/journal.pone.0004122.g007
Table 1. CD69 expression of monocultures after virus
infection.
sorted cells treatment CD69 expression (MFI)
a
CD56+ mock 0.9+/20.2
delNS1 10.4+/21.4
delNS1 inactivated 2.5+/20.5
CD3+ mock 1.5+/20.5
delNS1 5.6+/22.4
delNS1 inactivated 2.4+/20.6
CD19+ mock 2.3+/20.9
delNS1 9.8+/21.8
delNS1 inactivated 3.8+/20.8
aCD69 expression was measured by flow cytometry. Indicated numbers are the
mean intensity of fluorescence (MFI) and standard deviation. Two different
experiments for each cell type were carried out.
doi:10.1371/journal.pone.0004122.t001
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CD56+ cells showed a higher variation between different donors
(range of 20–80%). Since CD3+ cells neither produced type I nor
type II IFN we did not test them in this series of blocking
experiments. It should be noted that in order to investigate the
effect of IFNa on immune activation rather than on cancer cells
we have used the IFN resistant tumor cell line A375. In this cell
line direct effects of IFNa are absent [22], which was confirmed in
the cell line we used (data not shown).
After the activation phase cytotoxic cells exert the direct cell
killing by soluble factors but also by direct binding to the target
cell. We blocked mediators associated with cytotoxicity such as
NKG2D or TRAIL in isolated subpopulations. In our setting,
neither the inhibition of NKG2D in positively isolated CD56+,
CD14+ or CD3+CD56- cell populations nor the inhibition of the
TRAIL in positively isolated CD14+ cells had any effect on
delNS1 induced tumor cell killing. TRAIL inhibition in CD56+ or
CD19+ cells showed a slight inhibitory effect of 10% to 15% (data
not shown).
Effect of cytokines in whole PBMC cultures
In monocultures the cocktail of IFN antibodies had an effect in
blocking virus induced activation of cytotoxicity. We therefore
tested this cocktail in the total culture of PBMCs. However, this
antibody combination did not diminish the cytotoxic effect of
delNS1 activated PBMCs at any effector to target cell ratio tested
(data not shown).
Table 2. Cytokine production after virus infection of CD19+,
CD14+, CD56+, CD3+ monocultures and PBMCs.
Cell culture TNF
a IFNc
a IFNa
a IL-6
a
CD19+ 05 +/221 8 +/214 8 +/21
CD19+delNS1 105+/298 5+/22 134+/281 161+/290
CD14+ 2+/210 1 9 +/225 1 +/213
CD14+delNS1 798+/2254 9+/22 109+/216 447+/2164
CD56+ 7+/229 +/261 7 +/211 6 +/27
CD56+delNS1 46+/227 2622+/2230 150+/235 104+/23
CD3+ 05 +/241 8 +/218 +/27
PBMC 01 8 +/215 106+/227 28+/26
PBMC+delNS1 340+/2175 4279+/2542 5276+/2225 792+/2492
aDetermined by LuminexH and ELISA from supernatants 24h after infection in
pg/ml and representing the mean+standard deviation of two independent
experiments for each cell type.
doi:10.1371/journal.pone.0004122.t002
Figure 8. Role of interferon in the anti-tumor cytotoxic immune response by infected monocultures. CD14+ (a), CD56+ (b) and CD19+
cells (c) were infected with delNS1 virus (m.o.i.=0.02) and cultured for 24 hours with or without anti-IFNa, anti-IFNb, anti-IFNc and anti-IFNa-receptor
antibodies. Then cells were co-cultured with the target A375 cells for 24 hours and cytotoxicity was assessed. One representative result in percentage
of cytotoxicity is given for two experiments which were performed with cells derived from different donors.
doi:10.1371/journal.pone.0004122.g008
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blocking IFNs in the total culture of PBMCs, it is likely that IFNs
still have an effect in our system, since blockage of IFNs inhibited
activation of cytotoxicity in subpopulations. To compare the
cytotoxic activation of virus with type I IFN we treated PBMCs
either with recombinant IFNa (3,000 U/ml which equals
6,000 pg/ml) or with delNS1 virus at an m.o.i of 0.02. As shown
in figure 9a, recombinant IFNa induced a minor increase of
cytotoxicity as compared with non treated PBMCs, whereas the
tumor killing capacity of delNS1 infected PBMCs reached 98% at
the same effector-to-target ratio of 12:1.
Another well known type I IFN inducing agent is CpG, which
results in an enhanced cytotoxic activity similar to virus
stimulation. We now wanted to test whether the type I IFN
system could be circumvented by other mechanisms for activation.
We used CpG ODN 2216 known to stimulate NK- and T-cells via
IFNa and IFNb [23]. CpG stimulation induced an efficient
cytotoxic activity in PBMCs. In contrast to virus stimulation, CpG
stimulation of PBMCs could be partially blocked by the
combination of neutralizing antibodies against IFNa/b and the
type I IFN receptor from 90% to 60% at the effector-to-target
ratio of 25:1 (fig. 9b).
We further tested whether FASL, TRAIL or TNF effector
pathways were involved in the cytotoxic activity of virus-activated
PBMCs. We treated PBMCs with the respective neutralizing
antibodies separately or in combination one hour before co-culture
with tumor cells. Neither single application nor combination of
anti-FASL, anti-TRAIL and anti-TNF antibodies were able to
substantially decrease the cytotoxic effect of virus-activated
PBMCs towards tumor cells (data not shown).
Discussion
Here we demonstrated that stimulation of all predominant cell
populations of PBMCs with very low m.o.i of replication deficient
delNS1 influenza A virus led to activation of an innate cytotoxic
activity of those cells against tumor cells. Virus infection also
enhanced the cytotoxic effect of PBMCs derived from cancer
patients. Furthermore, the cytotoxic activity was not simply due to
allogenicity, since virally enhanced killing was also observed when
autologous murine spleen cells and tumor cells were used.
Generally, virus-induced innate cytotoxic immune response is
primarily ascribed to NK-cells [24,25] and to death-related
molecules produced by the monocytic lineages [19]. Lately,
TRAIL-mediated killing following influenza A virus stimulation
was described for a plasmacytoid dendritic cell line [2]. Here we
found that influenza A virus induced all major subsets of PBMCs
to mediate cytotoxicity. This included CD3+CD56- T-cells and
CD19+ B-cells. There are few reports concerning B-cell induced
cytotoxicity. One of the few examples is CpG stimulation of B-cells
resulting in an autocrine IFN signal and TRAIL expression which
mediates cytotoxicity [26]. B-cell mediated cytotoxicity might be
supported by the ability of B-cells to express T-cell polarizing
cytokines [27] and type I IFN as shown here. The B-cells induced
cytotoxicity might now explain the immediate protective effect of
these cells during virus infection, which remained unexplained up
to now [28]. Obviously, cells with specialized functions in the
adaptive immune system appear to have a remnant innate
cytotoxic activity upon initial stimulation. This might be relevant
in the initial immune response against the pathogen until more
differentiated activities of these cells have time to develop.
General reports analyzing virus-induced cytotoxicity have used
high multiplicity of infection reflecting the cytotoxic activity of the
virus-infected cells [19,29]. In contrast, we have used a very low
multiplicity of infection (as determined on Vero cells). Our work
now indicates that a small fraction of infected PBMCs is sufficient
for an activation of the majority of uninfected cells, which then
promotes the cytotoxic effect. Since the m.o.i. of an in vivo
infection is usually low, those secondary immunological phenom-
ena are interesting as they provide insights into the natural host
response. In our system virus induced cytotoxicity is dependent on
i) the primary activation of cells by the virus, ii) a second wave of
immune activation of non-infected cells, and iii) the direct
cytotoxic effect of the activated cells.
With respect to primary activation of cells by the virus we
found, that live virus is necessary to activate CD3+, CD14+ and
CD19+ cells, whereas heat inactivated virus is sufficient to activate
CD56+ cells. Heat inactivated virus lost the potential to generate
progeny RNA but still binds to the cellular receptor. Thus, the
viral haemagglutinin of heat inactivated virus might activate NK
cells via binding to the NKp46 receptor as has been shown for
Figure 9. Induction of an anti-tumor cytotoxic immune response by PBMCs infected with delNS1 virus or treated with rIFNa or CpG
ODN2216. (a) PBMCs were mock-treated, infected with delNS1 virus (m.o.i.=0.02) or stimulated with 3000 U/ml rIFNa and incubated for 24 hours.
Then PBMCs were co-cultured with the target A375 cells for 24 hours and cytotoxicity was assessed. One representative result in percentage of
cytotoxicity is shown of three independent experiments, each performed with PBMCs derived from a different donor. (b) PBMCs were incubated with
12.5 mg/ml CpG ODN2216 with or without addition of anti-IFNa, anti-IFNb and anti-IFNa-receptor antibodies, and incubated for 24 hours. Then
PBMCs were co-cultured with the target A375 cells for 24 hours and cytotoxicity was assessed. One representative result in percentage of cytotoxicity
is shown of two independent experiments, each performed with PBMCs derived from a different donor.
doi:10.1371/journal.pone.0004122.g009
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necessary in our system for activation of CD19+, CD14+ and
CD3+ cell this activation might depend on other mechanisms,
such as activation of RIG-1 which is induced by viral RNA [16].
We have further analyzed mediators associated with the second
wave of immune activation, the latter which stimulate the cells to
exert cytotoxic activation. We demonstrated that different subsets
of peripheral blood cells produce distinct cytokine patterns upon
virus stimulation indicating differential mechanisms of stimulation.
Thus, virus induced activation of cytotoxicity is not restricted to a
defined cytokine pattern.
Still, one group of cytokines, which have a relevant role in most
of the cellular subsets are IFNs. Type I and type II IFNs are widely
known for their involvement in virus induced activation of
cytotoxicity [29]. With respect to cancer, IFNs are associated
with adenovirus-mediated oncolysis in vivo [21]. Correspondingly,
we found that virus induced cytotoxic activation of IFNs
producing CD14+, CD19+ or CD56+ cells can be inhibited by
antibodies against those IFNs. However, CD3+ cells which do not
produce any IFNs were still able to induce cytotoxicity, indicating
activation by an IFN unrelated mechanism.
We demonstrated that PBMCs, which contain a mixture of IFN
dependent and independent cells, do not ultimately require the
presence of IFNs for virus activation of cytotoxicity, since blockage of
IFNs did not inhibit virus-induced cytotoxicity. The involvement of
the pathways other than IFNa in activation of cytotoxicity in PBMCs
was confirmed by experiments, which showed that IFNa alone
inducedamuchweakercytotoxicresponseinPBMCsascomparedto
the virus. In contrast to virus-induced cytotoxicity, cytotoxicity
induced by CpG could be blocked by antibodies against type I IFN,
indicating a high dependency of this drug on a single pathway. Thus,
our finding reveals that delNS1 virus induces a broader range of
stimulation than single molecules do. The redundancy of PBMC
stimulation by the virus might ensure efficient cytotoxicity of the
innate immune response, which might be important to clear viral
infection in vivo. Redundant mechanisms for PBMC activation are
most likely due to multiple cell-cell interactions of different cell type
which can occur in PBMCs. Reciprocal cell-cell interaction which
promote virus and non-virus induced activation of cytotoxicity have
beendemonstrated extensivelyforNKcellsand dendriticcells.Inthis
interaction dendritic cells provide cytokines such as IFNa [20] and
IL-12 but also activate NK cells via membrane bound receptors such
as NKG2D [29].
We have found that virus-stimulated CD56+ cells are able to
produce high amounts of IFNc. In contrast, Draghi et al. [29] and
He et al. [31] demonstrated that CD56+CD3- cells by themselves
are unable to generate IFNc production upon stimulation with
influenza virus. However, IFNc production by NK cells was
possible by co-cultivation with dendritic cells producing IL-12 or
with CD3+ cells producing IL-2, respectively. None of these
cytokines were induced in our CD56+ cell cultures. One difference
to the above mentioned studies is the fact that the CD56+
population we isolated still contained CD56+CD3+. Thus, the
interaction of CD56+CD3- and CD56+CD3+ cells might lead to
IFNc production via cell-cell interaction. However, CD56+CD3+
are not likely to produce IFNc on their own, since the CD3+
population containing this subset did not produced IFNc.A n
important aspect of our work is the fact that we have used a highly
immunogenic, replication defective mutant delNS1 virus, which
has been shown to induce a stronger innate immune response than
the wild type virus [13–15], whereas Draghi et al. [29] and He et
al. [31] used an influenza wild type virus. Moreover, we observed a
cytokine response when virus was used at low m.o.i. of 0.02,
whereas other authors only observed a cytokine response at an
m.o.i. of 10 or higher [29]. It is known that cytokine patterns of
immune cells following influenza A virus stimulation are critically
dependent on the m.o.i. [32]. At a high m.o.i. all cytokines
expressing cells might be directly stimulated and possibly lysed by
the virus. Being able to use the virus at a low m.o.i. we allowed a
second wave of cytokine stimulation. This secondary cytokine
wave is produced by cells not infected by virus, but activated by
cytokines and cell-cell interactions, which have been induced
previously by the initial infection. The cytokine composition of this
second wave seems to be different from that of the first wave.
With respect to the mechanism of the virus induced cytotoxic
effect our transwell analysis indicates that cell-cell interaction
mediate around half of the effect, whereas the other half was
mediated by soluble factors in the supernatant. Although we
assayed for a number of known cytotoxicity- associated soluble
factors such as TNF, TRAIL, FASL, NKG2D, perforin or
granzyme B, we could not identify single factors responsible for
this effect. It should be noted that we have used a type I IFN
resistant target cell line, which restricts the latter pathways. In
contrast, TRAIL in IFN sensitive target cells lines has been found
to play a role in virus stimulated cells, as has been shown for
Newcastle Disease virus (NDV) induced tumoricidal effects at high
m.o.i. [19]. Our analysis indicates that other factors are able to
compensate whenever TRAIL is not functional.
What are the implications of these findings for viral immunol-
ogy? First, during regular influenza A virus infection all activated
immune cells might initially exert cytotoxic functions thus limiting
initial viral spread by killing of virus infected cells. Second, we
regard the influenza A virus (delNS1) suitable for activation of a
cytotoxic immune response to cancer. This might be achieved by
ex vivo stimulation of peripheral blood cells with the virus and
subsequent adoptive transfer of viral activated cells into the
patient. Alternatively, delNS1 virus might be injected as oncolytic
viro-immunotherapy directly into the tumor with the intention to
induce cytotoxic activity in the anergic immune cells present in the
tumor tissue. In conclusion our data highlight the pleiotropic
functions of immune cells and provide further evidence of a close
inter-relation of the adaptive and the innate immune system.
Materials and Methods
Ethics Statement
The use of human peripheral blood has been approved by the
ethical committee of the Medical University of Vienna, Austria.
The use of animals has been approved by the Ministry of Science
of Austria.
Cells and Viruses
Sk-Mel 28 and A375 (melanoma), CaCo-2 (colon cancer), MCF-7
(breast carcinoma) and C-26 (murine colon cancer) were obtained
from the American Type Culture Collection (ATCC, Rockville,
MD). Cells were grown in DMEM (Bio Whittaker, Belgium)
supplemented with 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 10% heat-inactivated FCS (Gibco
BRL/Invitrogen
TM, California). GSJO, a primary medullary thyroid
carcinoma cell line (A.S, Department of Surgery, Medical University
Vienna) was cultured in RPMI-1640 medium supplemented with
glutamax-I at 50 mg/ml (Gibco BRL, Life Technologies, Scotland),
gentamicin (Gibco BRL) and 10% heat-inactivated FCS. Vero cells
(EC ACC, 88020401) adapted to grow in serum-free medium were
maintained in serum-free OPTIPRO medium (Invitrogen). The cells
were maintained in a humidified 5% CO2 atmosphere at 37uC. Cell
stocks were screened for mycoplasma by the polymerase chain
reaction method (Boehringer Mannheim, Germany).
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as described [33]. Heat-inactivation of PR8 virus was performed at
56uC for 30 min. For propagation of the viruses, Vero cells were
infected at a multiplicity of infection (m.o.i.) of 0.1 and incubated
in OPTIPRO medium containing 5 mg/ml trypsin (Sigma
Aldrich) at 37uC for 2–3 days. Virus concentrations were
determined by plaque assay on Vero cells.
Infection of PBMCs and monocultures with influenza
virus
After written informed consent, peripheral blood mononuclear
cells (PBMCs) from healthy donors and cancer patients were
isolated using Ficoll-Hypaque (Amersham Pharmacia Biotech AB,
Sweden) density gradient centrifugation. To deplete CD56+,
CD3+, CD14+ and CD19+ cells PBMCs were separated with the
corresponding microbeads (Miltenyi Biotec, Germany). All
depletions were carried out according to the manufacturer’s
instructions. Cell depletions were confirmed by flow cytometry.
Monocultures of human CD56+, CD3+, CD14+ and CD19+
cells were obtained by magnetic separation using cell specific
isolation kits (Milteny Biotec, Germany) following the manufac-
turer’s instructions. As determined by flow cytometry, the
procedure resulted in .90% pure cell isolates. Purity of CD56+
cells was 93.6+/23.7% and contained 15.2 +/29.6% CD56+/
CD3+ cells, 1.5+/20.8% CD14+ cells and 0.34+/20.47%
CD19+cells. Purity of CD19 cells was 93+/22.5% and contained
than 0.5+/20.4% CD56 cells, 3.7+/21.8% CD3+ cells 1.1+/
21.0% CD14+ cells. Purity of CD14+ cells was 93.3+/23.1%
and contained 0.3+/20.3% CD19+ cells, 1.8+/21.0% CD3+
and 1.16+/21.1% CD 56+ cells. Purity of CD3+ cells was 96.4+/
2 1.5% and contained 4.7 +/22.6% CD56+/3+, 0.5% CD14+
cells and un-detectable amounts of CD19+ cells. CD3+CD56-
cells were obtained by positive selection for CD3 cells followed by
depletion with CD56 specific antibody. Purity of CD3+CD56-
cells was 92+/21% and contained 1.8 +/20.9% CD14+ cells,
2.1+/20.5% CD56+ cells and 0.5+/20.3% of CD19+ cells.
Immediately after isolation PBMCs were infected with delNS1 or
PR8 virus at an m.o.i. of 0.02 in serum-free OPTIPRO medium
containing 4 mM glutamine. After incubation for 30 min. at room
temperature, the inoculums were removed and cells were washed.
Uninfected control cells were treated in the same manner except that
no virus was added (mock infection). Virus-activated and non-
activated PBMCs were cultured at a density of 5610
6 cells/ml in
RPMI-1640 medium supplemented with 2 mM glutamine and 10%
heat inactivated FCS for 24 h prior to co-culture with tumor cells.
To determine the amount of the infectious viral particles in the
supernatant of the virus-activated PBMCs, 1ml of supernatant was
centrifuged at 25 000 r.p.m. for 18h, at +4uC. The pellet was
resuspended in 500 ml of serum-free OPTIPRO medium contain-
ing 4 mM glutamine and 100 ml of that suspension was used to
determine the viral concentration via plaque assay on Vero cells.
For the stimulation of PBMCs with the CpG reagent
ODN2216, cells were cultured for 24 h (4610
6/ml) in the
presence of CpG ODN 2216 (12.5 mg/ml; VBC-Biotech, Austria)
in RPMI-1640 medium supplemented with 2 mM glutamine and
10% heat inactivated FCS.
To activate PBMCs with INFa, the recombinant form (Roche,
Switzerland) was added at the final concentration of 3000 IU/ml
16 h before cells were co-cultured with tumor cells.
Animals
Six week old BALB/c female mice were purchased from
Himberg (Austria). All animals were maintained at standard
conditions and fed a standard diet and water ad libitum.
Spleens were removed from mice under aseptic conditions and
homogenized. After the lysis of erythrocytes, cells were washed
and resuspended in serum-free OPTIPRO medium and infected
with virus as described above.
Cytotoxicity assay and inhibition experiments
Tumor cells were seeded in 96-well flat-bottom plates at a
density of 5610
3/well and left for several hours to adhere. The
cytotoxicity of influenza virus activated or non-activated PBMCs
was tested in duplicates against tumor cells at different effector-to-
target cell ratios after 24 h of co-culture. The tumor cell viability
was determined by colorimetric Easy for You Assay Kit (EZ4U
Kit, Biomedica, Austria) according to the manufacturers instruc-
tions and absorbance at 450 nm was measured spectrophotomet-
rically using a Dynatech Microplate Reader 5000 (Dynatech
Laboratories Inc., Chantilly, VA). Results were calculated as the
percentage of viability equaling the (OD of co-culture–OD of
PBMCs)/OD tumor cells6100.
To determine the sensitivity of cancer cells to the infection with
delNS1 virus, the tumor cells A375, Sk-Mel 28, CaCo-2 and
MCF-7 were seeded as described above and infected with a m.o.i.
of 0.2 and 0.02. The infected cells were cultivated in RPMI-1640
medium supplemented with 2 mM glutamine and 10% heat
inactivated FCS. The viability of the cells was determined 24h
after infection by colorimetric Easy for You Assay Kit.
For inhibition experiments, azide-free anti-TRAIL antibody
2E5 (5 mg/ml; Alexis, San Diego, CA) was added to effector cells
45 min before addition of target cells. Neutralization of NKG2D
was comparably achieved by 20 mg/ml of anti-NKG2D mAb
(R&D). Efficient blocking using those antibodies against TRAIL
and NKG2D has been proven in by Stary et al. [5]. FAS ligand
mediated killing was inhibited by anti-FAS-L mAb NOK-1
(20 mg/ml; Santa Cruz Biotechnology, Santa Cruz, CA). TNF
activity was blocked by adding human TNF RII/TNFRSF1B/Fc
chimera (20 mg/ml; R&D) to effector cells 1 h before co-culture
with target cells. For blocking of IFNa/b function, a combination
of polyclonal rabbit anti-IFNa (5,000 neutralizing U/ml) and
rabbit anti-IFNb (2,000 neutralizing U/ml) antibodies together
with 20 mg/ml of a mouse anti-human IFNa/b receptor chain 2
mAb were used (all from PBL, New Brunswick, NJ). Efficient
blocking using those antibodies against type I IFN has been proven
by Rothenfusser et al. [23]. For blocking of IFNc mouse anti-
human IFNc Ab (R&D) was applied. IFNa/b and IFNc function
was blocked immediately after infection of PBMCs with delNS1
virus.
Neutralisation of delNS1 virus was performed using sheep anti-
serum reagent to hemagglutinin (HA) of A/PR/8/34 virus (03/
242, NIBSC, Hertfordshire, UK) used at a final dilution of 1:40.
The blocking efficacy of the HA anti-serum was proven by the
inhibition of the Vero cells killing mediated by the infection with
delNS1 at the m.o.i. of 0.2. (fig. S3). For the neutralisation of
possible viral particles present on virus-activated PBMCs, PBMCs
were activated with the delNS1 as described above and HA anti-
serum was added to the PBMCs culture 1h prior the co-cultivation
with the tumor cells. The cytotoxicity of influenza virus activated
PBMCs was tested in duplicates against tumor cells at the
effector:target ratio=25:1 after 24h of co-culture by means of
colorimetric Easy for You Assay Kit.
Cell characterization by flow cytometry
The phenotype of delNS1 activated versus non-activated
PBMCs was determined by fluorescence analysis. Cells (3610
5)
were resuspended in 50 ml of assay buffer (PBS, 2% FCS and 1%
sodium azide) and incubated for 30 min at 4uC with fluorescein
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antibodies specific to cell surface markers. Monoclonal antibodies
specific for, CD3, CD14, CD56, CD19, perforin (Beckman
Coulter, France), granzyme B (Serotec, England) and NKG2D
(BD Pharmingen, Belgium) and the indicated isotype controls were
used to characterize cells. Cellular fluorescence was analyzed by
EPICS XL-MCL flow cytometer (Coulter, USA) with EXPO32
software (Beckman Coulter, France). 10,000 events were acquired
for each sample and the percentage of positive cells was reported.
Cytokine detection after infection with delNS1
PBMCs and monocultures of CD3+, CD14+, CD56+ or
CD19+ cells isolated from healthy donors were infected with
delNS1 (m.o.i.=0.02) and cultured for 24 hours in RPMI 1640
medium containing 10% FCS. The supernatant was then screened
with LuminexH for IL-1b, IL-4, IL-6, IL-8, IL-10, IL-12(p70),
IFNc and TNFa (Upstate, Temecula, CA). IFNa was detected by
ELISA (PBL Interferon Source, NJ).
Transwell cultures
Transwell cultures were established in 12 well plates (CostarH,
Corning Inc., USA) with Falcon
TM inserts (1 mm pore size, Becton
Dickinson, France). To keep the effector:target ratio=25:1
constant the number of PBMCs placed into the top chamber
and the number of tumor cells in the bottom chamber was
adjusted to account for the larger volumes used. The total volume
was 2 ml of medium. Controls consisting of cultures without
transwells were included. To retrieve supernatant only, the
PBMCs with or without delNS1 infection were cultured as
described above. Supernatant was transferred directly to tumor
cell cultures. All cultures were incubated for 24 h in a total volume
of 2 ml.
Supporting Information
Figure S1 Influenza A delNS1 does not induce tumor lysis.
A375, CaCo-2, Sk-Mel 28 MCF-7 were infected with the delNS1
virus at the m.o.i. of 0.2 and 0.02 or not infected (mock). The
viability of the cells was determined 24h after infection by means
of colorimetric Easy for You Assay Kit.
Found at: doi:10.1371/journal.pone.0004122.s001 (0.08 MB
DOC)
Figure S2 Neutralizing influenza heamagglutinin (HA) anti-
serum does not reduce cytotoxicity of delNS1-virus stimulated
PBMCs. PBMCs were mock-treated or infected with delNS1 virus
(m.o.i.=0.02) and were incubated for 24 hours. HA anti-serum
was added to the PBMCs culture 1h prior the co-cultivation with
the tumor cells. The viability of the tumor cells was determined
after 24h of co-culture. One representative result out of three
independent experiments, each performed with PBMCs derived
from a different donor, is shown.
Found at: doi:10.1371/journal.pone.0004122.s002 (0.71 MB TIF)
Figure S3 Neutralizing influenza heamagglutinin (HA) anti-
serum inhibits Vero cells killing mediated by the infection with
delNS1. The neutralizing HA-anti serum was added to the virus
suspension 1h prior infection of the Vero cells. The Vero cells were
infected at the m.o.i. of 0.2 either with the untreated or with the
HA-anti serum neutralized delNS1 virus. The control group was
left uninfected (mock). The viability of the Vero cells was
determined 48h after infection by means of colorimetic Easy for
You Assaz Kit.
Found at: doi:10.1371/journal.pone.0004122.s003 (0.05 MB TIF)
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